Cytek Biosciences

Q2 FY2026 EarningsQ2 FY26 revenue of $48.1M slightly missed the $48.6M consensus, while GAAP gross margin of 59.0% significantly beat the 51.5% expectation due to a one-time tariff refund. Despite strong instrument growth in the U.S. and China, GAAP EPS of -$0.09 was slightly below the -$0.085 mean estimate, driven by a 24% YoY surge in G&A expenses. Management raised the midpoint of FY26 revenue guidance to $209.5M, suggesting confidence in second-half AI-driven flow cytometry demand.